Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0024530 (
malaria
)
44,886
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Metabolism and disposition of most drugs used to treat
malaria
are substantially altered in
malaria
infection. Few data are available that specify effects of
malaria
infection on drug metabolism pathways in humans or animal model systems. In this report, studies were undertaken to determine the effect of Plasmodium berghei infection on cytochrome P-450 (CYP450) 2E1 and 3A2-mediated metabolism and enzyme expression in rat liver microsomes.
Malaria
infection (MAL) resulted in significant decreases in total cytochrome P-450 content (56%, P < 0.05) and NADPH cytochrome P-450 reductase activity (32%, P < 0.05) as compared to control (CON) rats.
Chlorzoxazone
4-hydroxylase activity (CYP2E1-mediated) showed no significant difference between CON and MAL microsomes while testosterone 6-beta-hydroxylase activity (CYP3A2-mediated) was reduced by 41% (P < 0.05) in MAL. Enzyme kinetic studies and immunoblot analysis indicate that the loss of activity for CYP3A2 in
malaria
infection is due to significantly decreased CYP3A2 protein expression. The altered expression of CYP450s in
malaria
infection should be taken into account when treating patients with
malaria
in order to minimize drug-drug interactions or toxicity.
...
PMID:Effects of Plasmodium berghei infection on cytochromes P-450 2E1 and 3A2. 1051 Jul 46